Journal
NATURE
Volume 488, Issue 7412, Pages 522-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature11287
Keywords
-
Categories
Funding
- James S. McDonnell Foundation [JSMF-220020206]
- Goldhirsh Foundation
- Cancer Prevention Research Institute of Texas [RP 100782]
- National Institutes of Health [R01 CA131313]
- [RO1 NS048192-01]
Ask authors/readers for more resources
Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year(1). This poor prognosis is due to therapeutic resistance and tumour recurrence after surgical removal. Precisely how recurrence occurs is unknown. Using a genetically engineered mouse model of glioma, here we identify a subset of endogenous tumour cells that are the source of new tumour cells after the drug temozolomide (TMZ) is administered to transiently arrest tumour growth. A nestin-Delta TK-IRES-GFP (Nes-Delta TK-GFP) transgene that labels quiescent subventricular zone adult neural stem cells also labels a subset of endogenous glioma tumour cells. On arrest of tumour cell proliferation with TMZ, pulse-chase experiments demonstrate a tumour re-growth cell hierarchy originating with the Nes-Delta TK-GFP transgene subpopulation. Ablation of the GFP(+) cells with chronic ganciclovir administration significantly arrested tumour growth, and combined TMZ and ganciclovir treatment impeded tumour development. Thus, a relatively quiescent subset of endogenous glioma cells, with properties similar to those proposed for cancer stem cells, is responsible for sustaining long-term tumour growth through the production of transient populations of highly proliferative cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available